Almotriptan malate is a well-established medication for the acute treatment of migraine headaches. Its efficacy is a result of precise chemical synthesis, where each intermediate plays a critical role. Among these, 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine, identified by its CAS number 334981-10-1, stands out as a key precursor.

This compound, characterized by its pale yellow solid appearance and a molecular formula of C11H16N2O2S, is synthesized through specific chemical routes. Its primary function is to serve as a foundational building block in the complex manufacturing process of Almotriptan. The purity of CAS 334981-10-1, typically specified at 98% or higher, is crucial for ensuring that the subsequent reaction steps proceed efficiently and yield an API that meets rigorous pharmaceutical standards.

For research scientists and procurement specialists in the pharmaceutical sector, understanding the properties and sourcing channels for this intermediate is vital. The compound's physical and chemical properties, such as its melting point (170-176°C) and solubility, are important considerations for handling and reaction optimization. As a sought-after pharmaceutical intermediate, its availability from reliable manufacturers and suppliers is a key factor in the drug production pipeline.

When considering the purchase of 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine, buyers often look for competitive pricing and dependable supply. Manufacturers in China are prominent suppliers of this chemical, offering advantages in terms of production capacity and cost. Engaging with these suppliers often involves requesting quotes for bulk quantities, understanding their production capabilities, and ensuring their adherence to quality control measures.

The journey from a chemical intermediate like 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine to a finished pharmaceutical product like Almotriptan malate is complex. It requires diligent attention to detail at every stage, from synthesis to formulation. By prioritizing high-quality intermediates and partnering with reputable manufacturers, the pharmaceutical industry can continue to deliver effective treatments to patients worldwide.